Bank of America’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.9M | Buy |
714,226
+193,479
| +37% | +$9.85M | ﹤0.01% | 1850 |
|
|
2025
Q4 | $25.9M | Sell |
520,747
-322,143
| -38% | -$15.7M | ﹤0.01% | 2076 |
|
|
2025
Q3 | $40.3M | Buy |
842,890
+338,584
| +67% | +$13.6M | ﹤0.01% | 1934 |
|
|
2025
Q2 | $15.9M | Buy |
504,306
+21,227
| +4% | +$680K | ﹤0.01% | 2789 |
|
|
2025
Q1 | $15.8M | Buy |
483,079
+109,991
| +29% | +$3.9M | ﹤0.01% | 2702 |
|
|
2024
Q4 | $13.5M | Sell |
373,088
-2,326
| -0.6% | -$81.9K | ﹤0.01% | 2648 |
|
|
2024
Q3 | $11.7M | Sell |
375,414
-30,187
| -7% | -$942K | ﹤0.01% | 2920 |
|
|
2024
Q2 | $10.8M | Buy |
405,601
+45,002
| +12% | +$1.3M | ﹤0.01% | 2867 |
|
|
2024
Q1 | $12.3M | Sell |
360,599
-4,079
| -1% | -$121K | ﹤0.01% | 2775 |
|
|
2023
Q4 | $10.6M | Buy |
364,678
+9,676
| +3% | +$257K | ﹤0.01% | 2833 |
|
|
2023
Q3 | $9.79M | Buy |
355,002
+52,325
| +17% | +$1.59M | ﹤0.01% | 2735 |
|
|
2023
Q2 | $9.1M | Sell |
302,677
-35,491
| -10% | -$1.24M | ﹤0.01% | 2801 |
|
|
2023
Q1 | $12.3M | Buy |
338,168
+1,343
| +0.4% | +$51.6K | ﹤0.01% | 2618 |
|
|
2022
Q4 | $12M | Buy |
336,825
+1,732
| +0.5% | +$60.2K | ﹤0.01% | 2505 |
|
|
2022
Q3 | $11.3M | Buy |
335,093
+12,148
| +4% | +$395K | ﹤0.01% | 2479 |
|
|
2022
Q2 | $9.34M | Sell |
322,945
-181,228
| -36% | -$5.19M | ﹤0.01% | 2771 |
|
|
2022
Q1 | $16.3M | Sell |
504,173
-30,746
| -6% | -$943K | ﹤0.01% | 2357 |
|
|
2021
Q4 | $15.6M | Buy |
534,919
+52,661
| +11% | +$1.6M | ﹤0.01% | 2462 |
|
|
2021
Q3 | $12.9M | Sell |
482,258
-99,793
| -17% | -$2.68M | ﹤0.01% | 2584 |
|
|
2021
Q2 | $17.9M | Buy |
582,051
+21,788
| +4% | +$668K | ﹤0.01% | 2244 |
|
|
2021
Q1 | $14.7M | Buy |
560,263
+31,410
| +6% | +$878K | ﹤0.01% | 2326 |
|
|
2020
Q4 | $13.3M | Sell |
528,853
-68,272
| -11% | -$1.47M | ﹤0.01% | 2247 |
|
|
2020
Q3 | $12.4M | Buy |
597,125
+65,801
| +12% | +$1.49M | ﹤0.01% | 2106 |
|
|
2020
Q2 | $12.6M | Buy |
531,324
+93,991
| +21% | +$2.08M | ﹤0.01% | 2018 |
|
|
2020
Q1 | $7.87M | Sell |
437,333
-13,927
| -3% | -$293K | ﹤0.01% | 2265 |
|
|
2019
Q4 | $10.7M | Sell |
451,260
-172,344
| -28% | -$4.19M | ﹤0.01% | 2490 |
|
|
2019
Q3 | $17.1M | Sell |
623,604
-132,566
| -18% | -$3.93M | ﹤0.01% | 1963 |
|
|
2019
Q2 | $25M | Sell |
756,170
-8,075
| -1% | -$277K | ﹤0.01% | 1670 |
|
|
2019
Q1 | $26.8M | Buy |
764,245
+58,018
| +8% | +$2.16M | ﹤0.01% | 1581 |
|
|
2018
Q4 | $23.5M | Buy |
706,227
+48,820
| +7% | +$2.1M | ﹤0.01% | 1545 |
|
|
2018
Q3 | $33.1M | Buy |
657,407
+138,012
| +27% | +$6.82M | 0.01% | 1413 |
|
|
2018
Q2 | $31.1M | Buy |
519,395
+185,763
| +56% | +$9.62M | 0.01% | 1445 |
|
|
2018
Q1 | $15.3M | Buy |
333,632
+48,286
| +17% | +$2.02M | ﹤0.01% | 2018 |
|
|
2017
Q4 | $11.4M | Sell |
285,346
-207,723
| -42% | -$8.21M | ﹤0.01% | 2323 |
|
|
2017
Q3 | $19.7M | Buy |
493,069
+140,763
| +40% | +$6.09M | ﹤0.01% | 1883 |
|
|
2017
Q2 | $15.2M | Sell |
352,306
-10,646
| -3% | -$379K | ﹤0.01% | 1979 |
|
|
2017
Q1 | $11.4M | Buy |
362,952
+35,069
| +11% | +$940K | ﹤0.01% | 2270 |
|
|
2016
Q4 | $8.28M | Sell |
327,883
-1,069
| -0.3% | -$23.9K | ﹤0.01% | 2475 |
|
|
2016
Q3 | $8.13M | Sell |
328,952
-46,058
| -12% | -$1.04M | ﹤0.01% | 2417 |
|
|
2016
Q2 | $7.64M | Sell |
375,010
-19,743
| -5% | -$350K | ﹤0.01% | 2447 |
|
|
2016
Q1 | $6.02M | Buy |
394,753
+1,831
| +0.5% | +$23.9K | ﹤0.01% | 2601 |
|
|
2015
Q4 | $5.28M | Buy |
392,922
+48,402
| +14% | +$749K | ﹤0.01% | 2887 |
|
|
2015
Q3 | $4.83M | Buy |
344,520
+310,234
| +905% | +$5.77M | ﹤0.01% | 2917 |
|
|
2015
Q2 | $582K | Buy |
34,286
+28,013
| +447% | +$399K | ﹤0.01% | 4576 |
|
|
2015
Q1 | $76K | Sell |
6,273
-2,927
| -32% | -$27.7K | ﹤0.01% | 5457 |
|
|
2014
Q4 | $76K | Sell |
9,200
-20,982
| -70% | -$176K | ﹤0.01% | 6081 |
|
|
2014
Q3 | $262K | Buy |
30,182
+25,182
| +504% | +$227K | ﹤0.01% | 5140 |
|
|
2014
Q2 | $55K | Sell |
5,000
-250,028
| -98% | -$2.23M | ﹤0.01% | 6587 |
|
|
2014
Q1 | $2.28M | Buy |
255,028
+245,700
| +2,634% | +$2.26M | ﹤0.01% | 3107 |
|
|
2013
Q4 | $70K | Buy |
9,328
+3,334
| +56% | +$23.3K | ﹤0.01% | 6369 |
|
|
2013
Q3 | $44K | Sell |
5,994
-14,833
| -71% | -$99.6K | ﹤0.01% | 6502 |
|
|
2013
Q2 | $134K | Buy |
+20,827
| New | +$123K | ﹤0.01% | 5969 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Bank of America's SUPN Position: Q1 2026 in Review
Bank of America increased its Supernus Pharmaceuticals (SUPN) stake by 37% in Q1 2026, buying an estimated $9.85M and bringing the position to 714,226 shares worth $36.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1850.
Bank of America first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.3M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Bank of America held 714,226 shares of Supernus Pharmaceuticals worth $36.9M as of Q1 2026.
- Bank of America bought 193,479 Supernus Pharmaceuticals shares in Q1 2026, an estimated $9.85M.
- Supernus Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1850 holding.
- Bank of America first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Supernus Pharmaceuticals position peaked at $40.3M in Q3 2025.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.